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Zusammenfassung
Hintergrund: Mit Hilfe eines etablierten Tiermodells zur Er-
zeugung lokalisationsspezifischer Knochenmetastasen in
der Nacktratte wurde ein semiquantitatives histologisches
Graduierungssystem zur schnellen Bewertung osteolyti-
scher Knochenmetastasen entwickelt. Das Graduierungssys-
tem liefert hinsichtlich der Metastasenlokalisation, deren
Ausmaß und Infiltrationsmuster wertvolle Zusatzinformatio-
nen zu den konventionellen histologischen Untersuchungs-
methoden. Damit kann beispielsweise auch die pharmakolo-
gische Wirkung von Bisphosphonaten auf die Knochenme-
tastasierung beurteilt werden. Material und Methoden:
Männlichen Nacktratten (n = 12 pro Gruppe) wurden Zellen
der humanen Brustkrebszellinie MDA-MB-231 in die Ober-
schenkelarterie inokuliert. Ab dem Auftreten radiologisch er-
kennbarer Osteolysen 18 Tage nach Inokulation erhielten die
Tiere bis zum Studienende (Tag 30) täglich entweder eine
subkutane Applikation einer Phosphat-Puffer-Lösung (Kon-
trollgruppe) oder Ibandronat (IBN, 10 μg P/kg; Behandlungs-
gruppe). Konventionelle Röntgenaufnahmen wurden an den
Tagen 18 und 30 nach Tumorinokulation angefertigt und die
Osteolysenflächen mittels Computerauswertung bestimmt.
Nach Studienende wurde der Metastasenbefall in beiden Ti-
biae sowohl konventionell histologisch als auch mittels des
neuen Graduierungssystems ausgewertet. Ergebnisse: Die
Metastasenfläche korrelierte mit der kummulativen Punkt-
summe des Graduierungssystems sowohl in der Kontroll-
gruppe (r = 0,762; p < 0,001) als auch in der Ibandronat-
Gruppe (r = 0,951; p < 0,001). Ebenso war die Osteolysenflä-
che eng mit der Punktesumme in beiden Gruppen korreliert
(r = 0,845 und 0,854; p < 0,001). Schlussfolgerung: Die signi-
fikante Reduktion von Knochenmark- und Kortikalisbefall
durch IBN deuten auf eine gute lokale Kontrolle des Meta-
stasenwachstums hin.
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Summary
Background: Using a nude rat model of site-specific
metastatic bone disease (MBD), we developed a semiquan-
titative histological score for rapid assessment of lytic le-
sions in bone. This provides additional information to con-
ventional histological measurement by clarifying the extent
and location of metastatic infiltration and the tumor growth
pattern. The score can also be used to assess the action of
bisphosphonates on bone metastases. Materials and Meth-
ods: Male nude rats (n = 12 per group) were inoculated with
the human breast cancer cell line MDA-MB-231 via the
femoral artery. Following appearance of radiographically
visible osteolytic lesions on day 18, the animals received
phosphate-buffered saline (PBS; controls) or ibandronate
(IBN, 10 μg P/kg) daily until day 30. Whole body radiographs
were obtained on days 18 and 30, and osteolytic areas (OA)
were determined by radiographic computer-based analysis
(CBA). On day 30, MBD was assessed in both tibias using
conventional histological CBA and the new scoring system.
Results: Metastatic tumor area correlated with the total sum
of the new score in both PBS- (r = 0.762) and IBN-treated an-
imals (r = 0.951; p < 0.001). OA correlated well with the total
sum in both groups (r = 0.845 and 0.854, respectively; p <
0.001). Conclusion: Significant reduction of bone marrow
and cortical infiltration of tumor cells with IBN suggested
local control of metastases. 
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Introduction
Bone metastases have significant impact on the prognosis and
quality of life of cancer patients, and their treatment is an im-
portant area of cancer care [1–3]. Preclinical evaluation of
drugs is a crucial step in the development of cancer treat-
ments, and has supported the widespread use of bisphospho-
nates in managing the skeletal complications of metastatic
bone disease [4]. The assessment of metastatic tumor burden
is a prerequisite for such analyses. Experimental models for
metastatic bone disease (MBD) and their outcomes are cur-
rently assessed by radiographic and histological quantification
of bone destruction. Conventional histomorphometry remains
the current gold standard for assessing bone lesion status.
However, this approach can be time-consuming, requires con-
siderable technical resources, and is not possible for advanced
tumors. 
Krempien et al. [5] have described a basic, 4-stage scoring sys-
tem for the histological evaluation of bone lesions in an ani-
mal model [5]. This score, ranging from normal bone histology
(0) to severe (+++) bone lesions, is a concise assessment tool
but is unable to provide information on metastatic growth pat-
terns, which is necessary for a detailed assessment of skeletal
destruction. As for conventional histomorphometry, this sys-
tem is also less useful once the tumor has destroyed a signifi-
cant proportion of bone. For advanced bone lesions, alterna-
tive criteria to evaluate metastatic burden have been devel-
oped, including complex 3-dimensional microtomographic
analyses [5–7]. However, while these techniques yield a wealth
of detail, they are not widely available and do not promote
high-throughput screening of potentially useful drugs.
We have developed a rapid, semiquantitative histological
score that could be used in addition to conventional histologi-
cal methods. Our aim was to identify succinct parameters for
the comprehensive analysis of patterns of osteolytic destruc-
tion and tumor cell infiltration, and to delineate the action of
bisphosphonate treatment on bone metastases. The present
study describes the proposed scoring system and its validation
against standard techniques in an animal model of site-specific
metastatic osteopathy [8]. A key goal was to ensure that the
new score should directly reflect quantitative evaluation of os-
teolyses, and still be informative when standard histomorpho-
metric techniques are not applicable (e.g. when bone destruc-
tion is far advanced). 
Material and Methods
Animals
A total of 24 athymic male nude rats (7–8 week old rnu/rnu Rowett nudes;
Harlan-Winkelmann, Borchen, Germany) were housed under specific
pathogen-free conditions. All animals had free access to tap water and
were fed ad libitum with a commercial standard feed (Sniff Spezialdiäten,
Soest, Germany). Experiments were approved by the governmental Ani-
mals Ethic Committee (Regierungspräsidium Karlsruhe, Germany).
Inoculation of Tumor Cells
Inoculation was achieved as described previously by Neudert et al. [8] and
Cailleau et al. [9]. In brief, 105 cells of the human breast cancer cell line
MDA-MB-231 (kindly provided by Dr. Theresa Guise, University of
Texas, San Antonio, USA) were suspended in 0.5 ml of phosphate-
buffered saline (PBS) and injected into the femoral arteries of both legs
via a polyethylene catheter (approximately 0.1 mm external diameter).
On average, osteolytic bone metastases became visible on hind limb radi-
ographs by day 18 post-inoculation (p.i.). All procedures were performed
under general anesthesia. 
Experimental Protocol
Inoculated rats were divided into 2 groups of 12 animals each. Following
the appearance of radiographically visible osteolytic lesions on day 18,
each group was injected subcutaneously with PBS (control) or iban-
dronate (IBN; Roche Diagnostics GmbH, Mannheim, Germany) daily for
12 days (to day 30 p.i.). IBN was dissolved in isotonic saline (adjusted to
pH 7.4) to give 10 μg P/kg/day, which corresponds to 51.4 μg of free acid
equivalents. This dose prevents tumor-related bone destruction in rats
[10]. Whole body radiographs were taken on days 18 and 30. On day 30,
the animals were sacrificed, and both tibias were removed and processed
for histological analyses, specifically to measure the metastatic area (MA).
Osteolytic areas (OA) were quantified using radiographic computer-
based analysis (X-CBA), as described below. Tumor extent at study termi-
nation was determined by histological computer-based analysis (H-CBA).
Metastatic deposits were evaluated using the new scoring system.
Radiographic Computer-Based Analysis
Whole body radiographs were taken during general anesthesia of the ani-
mals who were placed in an anterior-posterior orientation on a high-reso-
lution mammography film (Strukturix D4 DW ETE 18 × 24 cm, AGFA,
Köln, Germany). X-ray exposure (55 kV, 5 mA for 90 s) occurred in a ra-
diographic animal inspection unit (Torrex 120D, EG and G Astrophysics
Research, Long Beach CA, USA). Radiographs were scanned (resolution
of 480 dpi) and analyzed by 2 independent investigators blinded to the
protocol. Analyses were performed using specialist software at a magnifi-
cation of ×300 (CBA program, CBA 8000, Leica QWin Pro V2.0, Leica,
Bensheim, Germany). Osteolytic foci > 0.5 mm in diameter (detection
limit) were recognized as radiolucent lesions and manually delineated to
determine the number (n), perimeter (mm), and OA (mm2). Since initially
separate lesions showed a strong tendency to merge during tumor growth,
only the total OA per bone and animal was used for further analyses. An-
imals were then stratified into 2 groups for further analysis on day 30 p.i.
using OA measured on day 18 p.i. as the critical parameter. Since smaller
lesions were more likely to respond to IBN treatment than advanced
ones, an empirical cut-off of 6 mm2 was established based on OAs mea-
sured on day 18.
Histological Computer-Based Analysis
On day 30 p.i., local metastatic bone destruction was measured by histol-
ogy in both tibias. Bones were separated from surrounding tissue and
fixed in 10% neutral buffered formalin, and subsequently decalcified in a
14% EDTA solution. Following conventional processing and paraffin em-
bedding, sections (200 μM) were cut in the anterior, median, and posterior
third of each bone. Following staining with Masson-Goldner, sections
showing maximum tumor extent were selected and used to determine
MA. Metastatic foci were counted and their respective areas measured by
manual delineation (final magnification ×400). Results (number and area)
were processed using specialized software (CBA 8000, Leica QWin Pro
V2.0). All histological examinations were performed by 2 independent in-
vestigators blinded to the protocol.
Semiquantitative Histological Analysis
Bone sections used for the quantification of absolute MA were also em-
ployed for the semiquantitative evaluation using the new scoring system.
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al quadrants. Regardless of their number and position within the section,
all metastatic foci were assessed as though they comprised 1 cumulative
lesion. The area of this cumulative lesion was then estimated with refer-
ence to the size of 1 quadrant for that section. Scale bars and quantitative
estimates of lesion areas are therefore redundant for this analysis. For ex-
ample, if the total area of the combined foci was estimated to cover 1
quadrant (i.e., 25% of the total area) then this scored 1; if the total area of
combined lesions was 50% of the section (i.e., 2 quadrants) then this
scored 2. Total destruction of bone would therefore score a maximum of
4. Examples of how the scoring was performed are provided in figure 1.
ii) Topographical criteria of infiltration (T-indices): In order to estimate
the infiltration pattern of metastases, topographic localization to cortical
bone (TC), bone marrow (TM), and the invasion and/or infiltration of the
epiphyseal growth plate (TE) were evaluated separately. Scoring criteria
are summarized in table 1. Cortical bone (TC): In long bones, tumor-de-
rived osteolytic lesions typically begin in the medullary canal and eventu-
ally extend to the endosteal surface of the cortex. This results in a reduc-
tion in structural integrity and increased radiolucency [11]. Intact bones,
with no histological signs of cortical metastatic infiltration were scored 0.
In contrast, regions of cortical bone already destroyed by perforating le-
sions exhibit higher radiolucency. These regions were scored 1–3: 1 =
slightly infiltrated cortex; 2 = completely destroyed cortical structure on
one side; and 3 = destruction of both cortices of the section. Bone marrow
(TM): In contrast to cortical sites, widespread infiltration of bone marrow
does not induce equivalent lesions on radiographs. Consequently, when
bone marrow was affected (alone or in combination with other sites of le-
sion), 1 scoring point was added. Epiphyseal growth plate (TE): Small
metastatic lesions preferentially grow distal to the epiphyseal growth plate
of the proximal tibia. One point was scored for epiphyseal infiltration by
malignant cells. Tumors not only affecting the growth plate but also the
epiphysis scored an additional 2 points. 
iii) Quality of infiltration pattern (Q): The general appearance of tumor
growth patterns is heterogeneous. It is important to differentiate between
well-delineated and localized metastatic infiltration and diffuse and inva-
sive lesions. Localized and confined lesions accumulated a lower score (1
point) than diffuse invasive metastases (2 points). Both single parameters
(A, T, and Q scores) and the total cumulative score sum of all parameters
were used for correlation analysis with the absolute OA and MA deter-
mined by X-CBA and H-CBA, respectively. All parameters were ex-
pressed per affected tibia per animal.
Statistical Analyses
Statistical analyses were performed using the SAS software package (SAS
Institute, Cary, NC, USA). Descriptive data are expressed as mean ± stan-
The key output of this scoring system is the sum (Σ) of a number of dis-
tinct variables: tumor area (A), certain topographic indices (T), and the
mode of infiltrative tumor behavior (Q). This system attempts to reflect
the natural heterogeneity of bone metastases and include a full evaluation
of lesion status. This requires measurement of the extent and the specific
localization of metastatic infiltration. Osteolytic lesions typically first
occur in the upper half of the tibia. Therefore, histological sections were
bisected longitudinally with the proximal half used for analyses.
Defining the Score Components
Three main components were included in this analysis:
i) Infiltrated area (A): In order to estimate the relative proportion of
metastatic invasion in each section and to allow comparisons between
samples of different total bone area, each section was divided into 4 virtu-
Fig. 1. Evaluation of metastatic bone involvement using the new score
system. To estimate tumor area (A), proximal tibias were virtually divided
into 4 equal quarters and the metastatic area assessed for each (see dia-
gram top right). Each quarter with lesions scored 1 point (e.g., 2 a). In
comparison 2, 3, and 4 points were accrued by 2 b, 2 c, and 2 d, respective-
ly. For topographical criteria of infiltration (TC, TM, TE), complete de-
struction of cortical bone (TC) on one side is shown in 2 a (2 points), com-
pletely destroyed cortical structure on both sides is shown in 2 c and 2 d (3
points). The medullary canal is infiltrated in all sections in this figure; TM
therefore scored 1 in each case. Examples of the extent of epiphyseal in-
volvement (TE) are shown in 2 e, 2 f, and 2 g. A metastatic lesion growing
directly distal of the epiphysis causing part destruction of the growth plate
is show in 2 e (scoring 1 point). The same section is presented at a higher
magnification (×40) in 2 f. Complete destruction of the growth plate and
consecutive infiltration of the epiphysis (scoring 2 points) is shown in 2 g
(magnification ×25).
Table 1. Overview of the scoring system
Parameter Score Interpretation
A: tumor area (invaded quarters 1–4
of bone)
T: topography of invaded bone
TC (Cortex) 0 not affected
1 invaded
2 destructed on one side
3 destructed on both sides
TM (Bone marrow) 0 not affected
1 invaded
TE (Epiphysis) 0 not affected
1 invasion of growth plate
2 invasion of epiphysis
Q: Qualitative tumor growth 1 well delineated/encapsulated
2 invasive
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dard deviation (SD). Between-group comparisons were performed using
the Student’s t-test after testing for normal distribution of values, and p <
0.05 was considered significant. Correlations between parameters were
calculated as simple Spearman correlation coefficients.
Results
In both treatment groups, 1 animal died prematurely and was
excluded from analyses. 
Conventional Quantification
OAs (X-CBA) were visible in all inoculated animals on day 18
p.i.. In the IBN treatment group, the OA increased, remained
stable, or decreased over the 12-day treatment period, whereas
in the controls, a constant increase of OA was observed until
study termination. Following stratification for initial OA on
day 18 p.i., a qualitative assessment revealed the possibility of
a relationship between initial OA and treatment response.
This was reflected in the corresponding MA on day 30 p.i. [8]. 
Semiquantitative Analysis
The total score sum (Σ) was similar when both groups were
analyzed without further stratification (5.76 ± 3.91 vs. 5.01 ±
5.52 for control and IBN-treated animals, respectively). How-
ever, as previously described [8], smaller tumor deposits were
more likely to respond to treatment with IBN than larger le-
sions. We therefore applied an empirical cut-off of 6 mm2 to
further stratify groups by initial OA as determined by X-CBA
on day 18 p.i.. On average, IBN-treated animals with lesions 
< 6 mm2 had a significantly lower score sum than animals with
lesions > 6 mm2 (2.70 ± 4.99 vs. 8.84 ± 3.43, respectively; 
p < 0.01). When control animals were similarly stratified, no
significant differences in score sum were observed (p = 0.752).
Mean score values for single parameters and stratification are
shown in table 2. The extent of cortical infiltration (TC)
showed no difference between the control and IBN-treated
animals (1.76 ± 1.03, controls vs. 1.50 ± 1.46, IBN-treated ani-
mals). Again, after stratification for initial OA, the IBN-treat-
ed animals showed a significantly lower TC when OAs were 
< 6 mm2 on day 18 p.i. (0.70 ± 1.25, < 6 mm2 vs. 2.83 ± 0.41, 
> 6 mm2; p < 0.01). This difference in cortical infiltration was
also seen between IBN-treated animals and the controls for
osteolyses < 6 mm2 mainly reflecting the better drug response
of smaller tumor deposits (0.70 ± 1.25, IBN < 6 mm2 vs. 1.50 ±
1.18, controls < 6 mm2; p < 0.05). 
The evaluation of bone marrow infiltration (TM) showed a
significant decrease after IBN treatment (0.31 ± 0.48, IBN an-
imals vs. 0.71 ± 0.47, controls; p < 0.05). This effect was also ob-
served after stratification of initial OA in the smaller lesions
(0.20 ± 0.42, IBN < 6 mm2 vs. 0.60 ± 0.52, controls < 6 mm2; 
p < 0.05) and was absent when comparing greater (> 6 mm2)
metastases.
Epiphyseal infiltration (TE) did not differ between treated an-
imals and controls (0.69 ± 0.95, IBN vs. 0.47 ± 0.80, control an-
imals). However, after stratification for initial OA, a signifi-
cantly broader affection of the epiphysis in the IBN-treated
animals was seen when tumor lesions were > 6 mm2 compared
with the smaller lesions (1.17 ± 0.98, lesions > 6 mm2 IBN vs.
0.40 ± 0.84, lesions < 6 mm2 IBN; p < 0.01). This increased epi-
physeal infiltration in IBN-treated animals with greater tumor
Table 2. Radiographic (X) and histological (H) parameters determined by computer-based analyses (CBA) or semiquantitative scoring obtained on
day 30 p.i.; data are mean ± standard deviation and expressed in absolute values (mm2) or score; osteolytic (OA) and metastatic areas (MA) are shown
for the whole groups (total) and after stratification for initial OA on day 18 p.i. (< 6 mm2 and > 6 mm2, respectively as explained in the text)
Osteolyses Metastases Score
(OA) (MA) 
X-CBA, mm2 X-CBA, mm2 A TC TM TE ΣT Q score Σ
Controls (PBS)
Total 9.07 ± 5.02 6.5 ± 6.3 1.71 ± 1.31 1.76 ± 1.03 0.71 ± 0.47 0.47 ± 0.80 2.94 ± 2.00 1.38 ± 0.72 5.76 ± 3.91
< 6 mm2 (n = 5) 7.77 ± 5.01 5.91 ± 6.86 1.50 ± 1.43 1.50 ± 1.18 0.60 ± 0.52 0.50 ± 0.85 2.60 ± 2.22 1.11 ± 0.78 5.10 ± 4.36
> 6 mm2 (n = 6) 11.34 ± 4.44 7.37 ± 7.28 2.00 ± 1.15 2.14 ± 0.69 0.71 ± 0.49 0.43 ± 0.79 3.28 ± 1.70 1.43 ± 0.53 6.71 ± 3.25
IBN
Total 3.80 ± 3.42 8.3 ± 10.6 1.50 ± 1.71 1.50 ± 1.46 0.31 ± 0.48a 0.69 ± 0.95 2.56 ± 2.76 0.81 ± 0.83a 5.01 ± 5.32
< 6 mm2 (n = 5) 1.66 ± 1.91 4.6 ± 9.7 0.90 ± 1.66 0.70 ± 1.25a 0.20 ± 0.42a 0.40 ± 0.84 1.30 ± 2.50 0.50 ± 0.85 2.70 ± 4.9
> 6 mm2 (n = 6) 6.64 ± 2.87b 14.6 ± 10.8c 2.50 ± 1.38b 2.83 ± 0.41e 0.67 ± 0.52 1.17 ± 0.98b, e 4.67 ± 1.75e 1.67 ± 0.52d 8.84 ± 3.43e
ap < 0.05.
bp < 0.01.
cp < 0.01 between controls and IBN.
dp < 0.05.
ep < 0.01 within stratified subgroups in IBN-treated animals.
A = Estimated tumor area; TC = cortical infiltration; TM = infiltration of bone marrow; TE = infiltration of epiphysis; ΣT = sum of all topographical
parameters; Q = qualitative tumor growth; Σ score = total score sum (A+T+Q); PBS = phosphate-buffered saline; IBN = ibandronate.
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deposits remained significantly higher when compared with
the greater lesions in untreated controls (1.17 ± 0.98, lesions 
> 6 mm2 IBN vs. 0.43 ± 0.79, lesions > 6 mm2 in controls; 
p < 0.01). 
The sum of T indices (ΣT) did not reflect the IBN treatment
compared with untreated controls. It tended to show a higher
score in the IBN-treated animals when stratification for initial
OA was applied, but was not statistically significant (table 2).
The quality of metastatic growth pattern in terms of infiltra-
tion or delineation (Q) showed significantly better delineated
tumor lesions in the IBN-treated animals compared with more
invasive metastases in the untreated controls (means 0.81 ±
0.83, IBN vs. 1.38 ± 0.72, controls; p < 0.05). This effect was ab-
sent after stratification for OA on day 18. However, since le-
sions < 6 mm2 did respond significantly better to IBN treat-
ment than bigger metastases (means 0.50 ± 0.85 vs. 1.67 ± 0.52,
respectively), the effect of the unstratified data is mainly
caused by the smaller lesions.
Correlation between Score and Quantitatively Assessed 
Parameters (OA and MA)
The total score sum (Σ) significantly correlated with absolute
MA for both PBS- (r = 0.762; p < 0.001) and IBN-treated ani-
mals (r = 0.951; p < 0.001). Combined analysis of both groups
also revealed significant covariation (for MA, r = 0.870; 
p < 0.001; for OA r = 0.862; p < 0.001). This significant correla-
tion was also found when OAs were compared with the total
score sum in both groups (r = 0.845, controls and r = 0.854,
IBN; p < 0.001 for both) (table 3).
Further stratification for the assessed score subparameters
also showed a close correlation between tumor area (A) and
the CBA-assessed OA (figs. 2 a and b) and MA (figs. 2 c and
d). The quantitatively assessed MA estimated the score area
and reflected the wide range of tumor areas in tibias from
both groups. The close correlation between A and H-CBA (r =
0.702, controls and r = 0.970, IBN-treated animals; p < 0.001)
remained after stratification for initial OA on day 18 p.i.
Bone marrow and epiphyseal infiltration for controls (means
0.65 ± 0.49 and 0.47 ± 0.80, respectively) and IBN-treated ani-
mals (means 0.38 ± 0.50 and 0.69 ± 0.95, respectively) showed
no correlation to OA or MA on day 30 p.i. (correlation coeffi-
cient (r) ranged from –0.238 to –0.437; p < 0.01). Presence and
extent of epiphyseal infiltration appeared to reflect the local
situation in more detail, but did not significantly contribute to
the extent of measured OA and MA. As expected, the infiltra-
tion of bone marrow did not correlate with quantified tumor
areas on radiographs (OA). Assessment of invasive or well de-
lineated tumor growth as a qualitative aspect of the metastatic
aggressiveness (Q) on histological sections was also not corre-
lated with OA or MA. Comparison of the quantitatively
 assessed MA and OA were significantly correlated in both
PBS- (r = 0.705; p < 0.001) and IBN-treated animals (r = 0.970;
p < 0.001).
To focus on the additional information on metastatic tumor
growth that is provided by the score, the data were normal-
ized in order to eliminate the influence of MA. As a conse-
quence, the close correlation between histological assessment
and the score was reduced to r = 0.362. Therefore, it is most
likely that the score provides additional information on top of
MA, but to which extend cannot be proofed upon the pre-
sented data. 
Discussion
The aim of the present study was to develop a semiquantita-
tive tool to assess and stage bone lesions in a nude rat model
Table 3. Significant correlations (r values; all p < 0.001) between semi-
quantitative score and quantitative histological (H) and radiographic (X)
results
Score Radiography (X-CBA) Histology (H-CBA)
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ ⎯⎯⎯⎯⎯⎯⎯⎯⎯
Control IBN Control IBN
A 0.823 0.805 0.702 0.970
ΣT 0.752 0.862 0.753 0.927
Σ (total) 0.845 0.854 0.762 0.951
Histology (H-CBA) 0.705 0.970 – –
IBN = Ibandronate; CBA = computer-based analysis; ΣT = sum of all
topographical parameters.
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Fig. 2. Correlation of semiquantitative and quantitative histological
tumor assessment. The estimated tumor area (A) and the quantitatively
assessed metastatic (MA) and osteolytic areas (OA) determined by com-
puter-based analyses correlate closely in both control and IBN-treated an-
imals (n = 16 bones/treatment group). Apparently missing data points are
due to multiple projection of a single data point. Osteolytic area: (a) con-
trol animals, (b) IBN-treated animals; Metastatic area: (c) control animals,
(d) IBN-treated animals. For correlations see table 3.
a)                                           b)
c)                                           d)
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of MBD. The key criteria were to fill the gap between compre-
hensive (but labor-intensive) approaches and simple scoring
systems [5–7]. Overall, this score analysis showed good corre-
lation with established techniques, suggesting that this ap-
proach can be adopted in the experimental setting to measure
the extent of bone metastases. Although some individual in-
dices did not correlate when considered in isolation, these still
warrant inclusion as they not only contribute to the overall
score sum but are likely to provide additional descriptive de-
tail in the experimental setting.
In general, a drawback to histological assessments is a rela-
tively low sensitivity for osteolytic lesions. Here, we report a
lower detection limit of approximately 1.3 mm2. In the experi-
mental setting, sensitivity could be increased by preparing a
greater number of sections per bone. Although a greater num-
ber of sections will reduce the lower detection limit, this needs
to be balanced against the price of higher resource utilization.
Furthermore, the rate of apparent false-negative histological
sections in this study is likely due to the small number of sec-
tions per bone. The value and significance of histological
analyses is not the detection of small tumor lesions but the
confirmation or exclusion of other lesion characteristics. As
histological approaches are not usually used as a method for
screening bone lesions, comparison with radiological assess-
ments at this stage would yield limited benefits. In this study, 3
sections per bone provided sufficient tissue to perform de-
tailed evaluation of metastatic involvement. This suggests that
this new score is likely to reduce the need for time-consuming
multiple bone sections. 
Radiographic analyses of experimental tumor osteolyses have
been frequently employed [6]. There is uncertainty, however,
whether this technique allows full evaluation of tumor mass
and extent in bone. For example, using radiographic tumor
analysis, animals treated with antiresortive therapy (i.e., a bis-
phosphonate like IBN) can erroneously result in apparently
stable bone lesions. Using radiography, it is not possible to dif-
ferentiate between osteoclast inhibition or a reduction or inhi-
bition of the tumor growth itself. 
The data presented in this study suggest that the total score
sum (Σ) can predict OA on radiographs and that this may pro-
vide an alternative measure. Our data also suggests that strati-
fication of data, based on baseline tumor size may be essential
when using the score. Conventional radiographs provide a
summation of all histological-anatomically affected structures.
In this study, radiographic analysis had a higher sensitivity for
detection of bone metastases compared with the histological
analysis. When small bone lesions are present, this approach
may have practical benefits.
This new score proved useful in providing more detailed infor-
mation on the pattern of metastatic growth and the action of a
bisphosphonate by detecting differences in lesion status be-
tween IBN- and PBS-treated animals. In contrast to control
animals (100% of animals had an increase in OA), 81% of
IBN-treated animals had either stable or decreased metastatic
burden (1 IBN-treated animal achieved complete remission,
both on radiograph and histological sections). IBN treatment
significantly reduced the extent of bone marrow infiltration
(TM) and cortical infiltration (TC) in lesions < 6 mm2. Fur-
thermore, of particular note is the significant decrease in
metastatic aggressiveness (Q). This suggests the infiltration
pattern after IBN treatment is better delineated and not as in-
vasive as in the untreated controls. In contrast, epiphyseal in-
filtration was greater in the IBN treatment group when initial
OA size was > 6 mm2. We speculate that this might be an ef-
fect of the growing skeleton in adolescent rats; although tumor
cell adhesion is likely to be reduced on bisphosphonate-treat-
ed bone matrix, this is absent in the cartilage of the growing
epiphysis. This finding cannot, therefore, be directly translated
into the clinical situation in mature human patients with calci-
fied bone, but is worth investigating further in aged rats. 
The dose of IBN was obtained from another study in rats, in
which IBN significantly inhibited tumor-related bone destruc-
tion [10]. Comparable results were expected in the present
study thus allowing the assessment of the new score system in
an effective therapeutic setting. Although animal studies can
provide insight into efficacy or mode of action, a direct trans-
lation of the applied dose into the clinical situation requires
clinical trials.
This study has certain limitations, for example, we only ana-
lyzed a limited number of time points. However, this is unlike-
ly to affect the validity of the score as it is based on the assess-
ment of histological and anatomical structures which are pre-
sent throughout all stages of metastatic growth. We also recog-
nize that osteoblastic lesions were not assessed during this
study. Although yet to be confirmed, we would expect this
score to be of use when examining osteoblastic lesions (and
indeed mixed lesions) as these too have measurable histologi-
cal characteristics which are discernable from surrounding
healthy bone. Although the correlation with radiographic
scores will need further clarification (due to differences in ra-
diolucency with osteoblastic growth) it will still be possible to
evaluate tumor area, infiltration, and growth patterns in os-
teoblastic models. As only one bone lesion model, this raises
the question of whether it would apply to other animal models
or tumor cell lines. Although this clearly will need confirma-
tion by additional studies, we fully expect the score to be
transferable to other laboratory animal models as anatomical
and histological features of the skeleton are similar. Similarly,
we predict that the score will apply to other tumor cell lines as
it is the extent and pattern of bone destruction which is being
measured as a result of inoculation, not a direct characteristic
of the cancer cells themselves. 
It should be noted that this scoring system does not measure
total tumor burden. This may limit its use to those cancer
models in which focal lesions have been either previously
identified or, as in this study, generated by focal inoculation.
This score was designed to be used primarily in conjunction
with focal inoculation targeting the skeleton only. Measuring
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overall tumor burden (e.g., visceral metastases) was not an ob-
jective when designing this score.
In conclusion, our novel semiquantitative histological score
provides a rapid and reliable means to assess the extent of
metastatic bone involvement in the laboratory. This score can
provide more detailed information on metastatic tumor cell
infiltration of bone that is not captured by conventional mea-
sures of tumor burden. It also offers an alternative when radi-
ographic analytical methods are unavailable or inapplicable
(i.e., when tumor destruction of bone is significant). While the
score does not provide the high-resolution detail of 3-dimen-
sional volumetric measurement, it has value as an accurate,
rapid, and conveniently applicable assessment tool. The scor-
ing system was also sensitive to histological changes in bone
following treatment with a bisphosphonate. Significant reduc-
tion of bone marrow and cortical infiltration following expo-
sure to IBN suggests that local control of metastases can be
detected, as shown by reduced tumor cell infiltration and
greater definition and delineation of the overall lesion area. 
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